Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

March 01, 2022

Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.

February 03, 2022

January 12, 2022

Liquid biopsies are critical in understanding oncogenic drivers and resistance mechanisms in patients with non–small cell lung cancer.

January 10, 2022

Wade T. Iams, MD, discusses the need to establish the clinical utility of circulating tumor DNA testing in lung cancer.

January 07, 2022

Kristen K. Ciombor, MD, MSCI, discusses data evaluating the utility of rechallenging with EGFR inhibitors in RAS/RAF wild-type colorectal cancer.

January 04, 2022

With an influx of new trials examining the use of anti-EGFR treatments in patients with advanced colorectal cancer, attention must be paid to finding the optimal window in which to give these therapies to maximize benefit.

January 03, 2022

Dr Gilbert discusses her new role as associate director for research, education, and professional development at Vanderbilt University Medical Center and shares some of her short- and long-term goals in this position.

December 20, 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of panitumumab in the maintenance treatment of patients with RAS wild-type metastatic colorectal cancer.

November 16, 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of anti-EGFR therapy for the frontline treatment of patients with metastatic colorectal cancer.

October 29, 2021

Bhagirathbhai Dholaria, MBBS, discusses patient characteristics in the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

October 07, 2021

Jill Gilbert, MD, discusses overcoming imposter syndrome in fellowship.

September 30, 2021

Bhagirathbhai Dholaria, MBBS, discusses the rationale for the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

August 22, 2021

The ability to reflect and boldly choose a professional identity should be discussed, encouraged, and nurtured in every individual.

August 04, 2021

At a median follow-up of 42.8 months, frontline pembrolizumab plus axitinib continued to yield improved outcomes over sunitinib in patients with advanced clear cell renal cell carcinoma.

July 15, 2021

Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.

June 03, 2021

Dr. Rini discusses unique elements of the TIVO-3 trial, the significance of the FDA approval of tivozanib in advanced RCC, and potential next steps for research with the TKI in the paradigm.

May 21, 2021

Hematology/oncology programs can make it easier and more rewarding for would-be mothers to participate in fellowship.

May 20, 2021

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.

May 17, 2021

Brian I. Rini, MD, discusses the results of an exploratory analysis of the phase 3 IMmotion151 trial in metastatic renal cell carcinoma.

April 26, 2021

Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.